Cumulus Neuroscience and Muse bring lab-grade sl
Author: Michael
As investment fuels brain diagnostics, Amprion’s expansion highlights growing belief that better tests are just as important as better drugs. The race against neurodegenerative disease has largely focused on finding the next breakthrough drug. However, a growing number of researchers are beginning to ask a different question: what if one of the biggest bottlenecks isn’t the medicine, but knowing exactly who should receive it? That question sits at the heart of two conversations reshaping the field. The first is about de-risking drug development. Every failed clinical trial represents years of work and billions of dollars, but sometimes a promising therapy…
Swiss-developed system brings longitudinal blood
Debut and Natura team up to develop an AI-discov
True cellular therapeutics require stem cells bu
Report says performance health startup winding d
New platform reflects growing demand for persona
Pilot research suggests Basis may ease menopausa
FDA clearance for all skin types is making regen
New assay could make tracking Alzheimer’s prog